Treatment of liver metastases from colorectal cancer: what is the best approach today?
Liver is the common site for metastases from colorectal cancer. The 5-year overall survival rate of patients following radical operations is 25%. Surgery can be carried out in only 10-15% of the patients, yet it remains the potential curative treatment for resectable lesions. For the unresectable cancers, only chemotherapy is recommended. New drugs such as Irinotecan prolongs the overall survival of patients affected by advanced disease. In patients with unresectable metastases at diagnosis, pre-surgical treatment with Oxaliplatin leads to reduction of the lesions, allowing resection in 16% of cases. Chemotherapy may be delivered directly into the liver via the hepatic artery. No, clinical trials, to date, have shown convincing survival results in patients treated with this procedure. Combined hepatic artery and systemic treatment may provide a new strategy as adjuvant therapy for patients undergoing resections.
Biasco
G
G
Institute of Hematology and Medical Oncology L. e A. Seràgnoli, University of Bologna, S. Orsola-Malpighi Hospital, Italy. gbiasco@med.unibo.it
Gallerani
E
E
D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D013505:Digestive System Surgical Procedures / Q000639:trends; D004358:Drug Therapy / Q000639:trends; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D012008:Recurrence; D015996:Survival Rate